Mutations in RAS have been found in \>80% of cancer indications ([@r1], [@r2]) with the majority occurring in KRAS ([@r3]). These tumors are one of the largest unmet clinical needs in oncology. The foundation and advancement of our understanding of this disease subset is due to the vast experimentation utilizing *Kras* mutant genetically engineered mouse models (GEMMs). However, the models themselves are poorly characterized. For human tumors, defining the genomic landscape has significantly improved our understanding of cancer etiology and revealed subpopulations uniquely susceptible to therapeutic intervention ([@r4][@r5][@r6]--[@r7]). Similarly, interrogation of the genomic landscape of several cancer GEMMs has identified cooperating genomic events ([@r8][@r9]--[@r10]). The genomic and matched transcriptional landscape of specifically *Kras* mutant GEMM tumors, however, remains largely undefined, making it challenging to translate response data into clinical application. Furthermore, substantial variability in growth rate, survival, and drug response has been observed in *Kras* mutant models despite the shared initiating event ([@r11], [@r12]). Although multiple factors, including tissue type, cell of origin, and stromal cell involvement may contribute to tumor biology, we hypothesized that cooperating events---spontaneously acquired during tumor development---may underlie these heterogeneities. In this study, we set out to more thoroughly define the genomic and transcriptional landscapes of three established *Kras* mutant GEMMs and to assess the implication of tumor heterogeneity on treatment susceptibility and tumor evolution under selective pressure of drug therapy.

Results {#s1}
=======

Spontaneous Acquisition of Genomic Aberrations in KrasG12D-Initiated GEMM Tumors. {#s2}
---------------------------------------------------------------------------------

To better define the genomic landscape of established *Kras* mutant tumor models, we focused on three models of *Kras* mutant cancer: a nonsmall cell lung cancer (NSCLC) model with adenovirus-induced expression of *KrasG12D* and homozygous *p53* targeting (KP:*Kras*^*LSL.G12D/wt*^*;p53*^*frt/frt*^) ([@r11], [@r13]), and two models of spontaneous pancreatic ductal adenocarcinoma (PDAC) initiated by Pdx1-driven recombinase expression in the developing pancreas to induce *KrasG12D* expression, with either heterozygous loss of *p16/p19* (*Cdkn2a*) in the presence of *p53* mutation (KPR:*Kras*^*LSL.G12D/wt*^*;p16/p19*^*fl/wt*^*;p53*^*LSL.R270H/wt*^*;Pdx1.Cre*) or with homozygous targeting of *p16/p19* (*Cdkn2a*) in the absence of *p53* mutation (KPP: *Kras*^*LSL.G12D/wt*^*;p16/p19*^*fl/fl*^*;Pdx1.Cre*) ([@r11], [@r14]) ([Table S1](#d35e486){ref-type="supplementary-material"} and [Dataset S1](#d35e489){ref-type="supplementary-material"}).

We analyzed the profiles of exomes and matched transcriptomes of 221 *KrasG12D*-initiated GEMM adenocarcinomas ([Table 1](#t01){ref-type="table"}). Protein-altering mutations (PAMs) were found in \>95% of tumors, with 1,908 total PAMs and on an average of nine PAMs per tumor ([Table 1](#t01){ref-type="table"} and [Fig. S1*A*](#d35e486){ref-type="supplementary-material"} and [Dataset S2](#d35e508){ref-type="supplementary-material"}). There were no recurrent hotspot mutations ([Dataset S2](#d35e508){ref-type="supplementary-material"}). PAM load varied widely among tumors even when isolated from the same animal ([Fig. 1*A*](#fig01){ref-type="fig"}), implying independent mutational susceptibility despite the shared host. In addition, there was no significant difference in PAM load between the models regardless of *p53* status (ANOVA, *P* = 0.94). Twenty percent of PAMs are expressed ([Dataset S2](#d35e508){ref-type="supplementary-material"}), consistent with recent work in human genomics studies where RNA-seq--based confirmation of protein-altering somatic variants ranged from 19 to 38% ([@r15][@r16]--[@r17]). When comparing to patient tumors, we found that the mutational frequency in GEMM tumors is 7- and 10-fold lower than in human *KRAS* mutant pancreatic and lung adenocarcinoma (never smokers), respectively ([Fig. 1 *B* and *C*](#fig01){ref-type="fig"}).

###### 

Summary of mutations in *Kras*^*G12D*^ GEMM tumors

                                 NSCLC (KP)   PDAC (KPP)   PDAC (KPR)
  ------------------------------ ------------ ------------ ------------
  Matched pairs analyzed         115          66           40
  Median no. of all mutations    16           14           18
  Average no. of PAM per tumor   8.5          9            8.5
  Median no. of PAM per tumor    6            5            6
  Average no. of PAM per Mb      0.23         0.24         0.23
  Maximum no. of PAM             34           140          53
  Minimum no. of PAM             0            0            0

![Genomic landscape of *KrasG12D*-initiated GEMM tumors. (*A*) The number of protein-altering mutations per tumor (circle) organized by animal along the *x* axis in PDAC KPP (cyan, *n* = 66), PDAC KPR (red, *n* = 40), and NSCLC KP (orange, *n* = 115). The three KPP tumors with PAM frequency \>10-fold the average have either a nonsense *Brca2* mutation or a missense *Brca1 or Bap1* mutation. (*B* and *C*) PAM load in human and murine tumors are summarized as the number of protein-altering mutations per megabase for NSCLC GEMM and human LUAD tumors from TCGA (*B*), and KPP and KPR PDAC GEMM and human PDAC tumors from TCGA (*C*). (*D*) Significance (GISTIC2.0 *q* value) of focal genomic regions that are gained (in red) or lost (in blue) in NSCLC KP model. *q* values are saturated at 10^−20^ for visual clarity. Examples of known cancer-related genes in significantly altered regions are annotated. (*E*) Comparison of gene-level prevalence of genomic alterations (copy number aberration and/or mutation) in GEMM tumors and the corresponding cancer indications from human TCGA restricted to *KRAS*-mutant tumors. Shown are genes that are significantly altered (GISTIC2.0, MutSig2CV) in either species and that are \>5% prevalent in *KRAS*-mutant human tumors (NSCLC, 2,024 genes; KPP, 1,307 genes; KPR, 1,330 genes). Cancer-related genes are annotated in red. The extent of commonalities and exclusivities between human and murine is indicated as a percentage of altered genes (gray) and altered cancer genes (red) in four quadrants, defined by a 20% prevalence threshold in either species. Four hundred ninety-three genes are significantly altered (GISTIC2.0) and prevalent (≥20%) in KP NSCLC GEMM tumors, of which 46% are murine-exclusive (≤1% in human). Twenty-five of 493 genes are cancer-related, of which eight are murine-exclusive (*Dnmt1*, *Als2cl*, *Rrp9*, *Tcf3*, *Fstl3*, *Apc2*, *Gna11*, *Ddx6*). None of the seven significantly altered (GISTIC2.0 or MutSig2CV) and prevalent (≥20%) genes in human *KRAS* mutant lung tumors are exclusive to human. In human PDAC tumors, there are 10 significant and prevalent events, of which 4 occur in cancer-related genes. Only one of those, *SMAD4*, is human-exclusive in comparison with both PDAC models. In KPP GEMM tumors, five genes with significant and prevalent copy number alterations were found, of which one is cancer-related and engineered (*Kras*). The four other genes occur at or near the region of focal amplification on chromosome 6. In KPR GEMM tumors, only two genes had significant and prevalent CNAs with one being engineered, *Cdkn2a*.](pnas.1708391114fig01){#fig01}

In contrast to PAMs, extensive and strongly recurrent patterns of copy number alterations (CNA) were seen in all three models ([Fig. 1*D*](#fig01){ref-type="fig"} and [Fig. S1*B*](#d35e486){ref-type="supplementary-material"}), including several genes known to drive cancer by this mechanism ([@r18]). Focusing on regions of recurrent amplification or deletion (GISTIC2.0 *q* value \<0.1; [Datasets S3--S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1708391114/-/DCSupplemental)), NSCLC KP GEMM tumors displayed the most abundant CNAs. Cancer genes in those recurrently altered regions are, for example, *Met*, *Keap1*, *Smarca4*, *Pml*, *Als2cl*, *Stk11*, *Gna11*, and *Akt1*. Focal amplification of a region harboring *Kras* in PDAC KPP GEMM was the only prevalent event in that model ([Fig. S1*B*](#d35e486){ref-type="supplementary-material"}). Indeed, cooperating genomic alterations are acquired during tumor development in *Kras* mutant models. However, distinct from human tumors, PAMs are rare in *Kras* mutant GEMM tumors and instead CNAs are prevalent.

Shared Prevalent Gene Alterations Between Murine and Human Tumors. {#s3}
------------------------------------------------------------------

To determine the fidelity of genes spontaneously altered in the GEMM tumors relative to human *KRAS* mutant tumors, we directly compared the alterations observed in the *Kras* mutant GEMM tumors to those in corresponding *KRAS* mutant human indications in an unbiased manner, focusing on genes that are significantly altered in either species as per GISTIC2.0 or MutSig2CV. Using the prevalence of genetic alterations (CNA and mutations) per gene in *Kras* mutant tumors from both species ([Fig. 1*E*](#fig01){ref-type="fig"} and [Datasets S3--S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1708391114/-/DCSupplemental)), we found that the majority of all genes are altered in \<20% of tumors from either species. Moreover, there is little enrichment of alterations within cancer genes, relative to all genes in both species. Exclusivity of gene alterations by species (≥20% prevalence in one and ≤1% in the other) was observed, although rare overall. *SMAD4* is an example of a human exclusive gene alteration in pancreatic cancer that is notably absent from both PDAC KPP and KPR GEMM tumors. In NSCLC KP, four cancer-related genes were observed to occur with ≥20% prevalence in both species, two of which are genes genetically engineered in the murine tumors, *Kras* and *Trp53*, and two are spontaneously acquired, *Keap1* and *Stk11*. Thus, despite the divergence of the type of genetic alteration, PAM vs. CNA in human and GEMM, respectively, the GEMM tumors acquire aberrations in genes frequently observed in *KRAS* mutant human tumors.

Intratumoral and Intertumoral Genomic Heterogeneity in Kras-Mutant GEMM Tumors. {#s4}
-------------------------------------------------------------------------------

Although spontaneously acquired genetic alterations were found in all *Kras*-initiated GEMM tumors, we sought to interrogate their frequency within tumors as a means to gauge their contribution to tumorigenesis and maintenance. Most mutations observed in the GEMM tumors are clearly subclonal ([Fig. 2*A*](#fig02){ref-type="fig"} and [Fig. S1 *C*--*F*](#d35e486){ref-type="supplementary-material"}) and private, strongly suggesting that these are unlikely driver events required for tumor progression.

![Intratumoral and intertumoral genetic heterogeneity in *Kras*-mutant GEMM tumors. (*A*) Distribution of the variant allele frequency for all observed PAMs from regions that remain copy number neutral, by model. The median of variant allele frequency per model: PDAC KPP, 0.06; PDAC KPR, 0.08; NSCLC KP, 0.1. (*B*) *KrasG12D* allele frequency associated with *Kras* copy number reveals selective amplification of G12D allele. Rare loss of the wild-type allele was observed (green halo): KPP *n* = 63, KPR *n* = 40, KP *n* = 115. (*C*) The distribution of genomic reads with G12D relative to the total number of reads mapping to *Kras* in normal tissues (light blue) or in tumors (pink). (*D*) FISH image from a representative KPP PDAC tumor for *Kras* (red) and a control gene (green). (*E*) FISH image from KP NSCLC tumors for *Kras* (red) and a control gene (green). *Insets* demonstrate adjacent cells with divergent *Kras* gains (white arrows, *Kras*). (*F*) FISH from two representative KP NSCLC tumors for *Keap1* (red) and a control gene (green). Cells with heterozygous loss of *Keap1* (solid white circles) and cells with homozygous deletion of *Keap1* (dashed white circles) are observed within the same lesion.](pnas.1708391114fig02){#fig02}

Because allelic imbalance at the *Kras* locus is reported to be critical for in vivo *KrasG12D*-initiated tumorigenesis ([@r8], [@r19][@r20]--[@r21]), we assessed the prevalence and clonality of alteration of the driving oncogene. We observed *Kras* CNAs in all *KrasG12D*-initiated GEMM tumors, but the extent and penetrance varied widely ([Fig. 2*B*](#fig02){ref-type="fig"}). Ninety-one percent (58/64) of PDAC KPP tumors had focal gain or amplification (≥4 copies) of *Kras* with 3--26 copies (38% had \>6 copies). Amplification was predominantly of the mutant allele (Kolmogorov--Smirnov test, *P* \< 2.2*e*-16; [Fig. 2*C*](#fig02){ref-type="fig"}). Fluorescent in situ hybridization (FISH) of *Kras* revealed amplification in 38--57% of cells within tumors, with individual amplified cells carrying 20--60 copies, illustrating a high degree of intertumoral and intratumoral heterogeneity ([Fig. 2*D*](#fig02){ref-type="fig"} and [Fig. S2](#d35e486){ref-type="supplementary-material"}). PDAC KPR tumors, however, showed *Kras* gain in 23% (9/40) of tumors, due to broad gain of chromosome 6 in 20% (8/40) of tumors ([Fig. S1*B*](#d35e486){ref-type="supplementary-material"}). Loss of the wild-type *Kras* allele was rare (3% in both PDAC KPP and KPR) ([Fig. 2*B*](#fig02){ref-type="fig"}). For NSCLC KP, 92% of tumors showed allelic imbalance of *Kras*, of which 90% (95/106) gained only a single copy of *Kras* and 4% lost the wild-type allele, consistent with previous reports ([@r19]) ([Fig. 2*B*](#fig02){ref-type="fig"}). Again, single-cell analysis of *Kras* copy number aberrations revealed significant intratumoral heterogeneity of *Kras* in NSCLC KP tumors ([Fig. 2*E*](#fig02){ref-type="fig"}). Such intratumoral heterogeneity was also observed following single-cell analysis of *Keap1* in NSCLC KP tumors, where individual lesions harbor cells experiencing heterozygous or homozygous deletion of *Keap1* ([Fig. 2*F*](#fig02){ref-type="fig"}). Together these data reveal allelic imbalance as a commonly shared occurrence across *Kras*-initiated GEMM tumors. Moreover, single-cell analysis reveals broad intratumoral genomic heterogeneity of observed aberrations irrespective of model.

Cooccurring Genomic Alterations in Murine and Human Kras Mutant NSCLC KP Tumors. {#s5}
--------------------------------------------------------------------------------

The NSCLC KP tumors demonstrated the most diverse genomic landscape ([Fig. 1 *D* and *E*](#fig01){ref-type="fig"}) among the *KrasG12D*-initiated models. Given such complexity and heterogeneity, we sought to clarify which cooccurring events harbor functional relevance within these tumors. To this end, we utilized the matched transcriptomic data from each tumor to identify genes whose expression levels reflect the underlying copy number alterations. Among the 115 NSCLC KP tumors, 141 focal regions were significantly gained or lost when considering both prevalence and magnitude of aberration ([Fig. 1*D*](#fig01){ref-type="fig"}; GISTIC2.0), with 2,274 expressed genes residing in these regions. Only 19% (438/2,274) of these genes have significant congruent copy number and expression changes (Spearman correlation ≥ 0.3), suggesting that only some CNAs lead to detectable expression changes.

To better understand the impact of cooperating or recurrent genomic events in the NSCLC KP tumors and enable comparison with human tumors, we focused on established cancer genes ([@r4], [@r22], [@r23]) that are located in significantly altered CNA regions in NSCLC KP tumors with congruent expression changes (≥0.25) (27 genes; [Dataset S6](#d35e1091){ref-type="supplementary-material"}). In parallel, we obtained the most common reported events (both mutations and CNAs) in human The Cancer Genome Atlas (TCGA) lung adenocarcinoma ([@r18]). We found five commonalities: *Met*, *Keap1*, *Smarca4*, *Nkx2-1*, and *Stk11* ([Fig. 3*A*](#fig03){ref-type="fig"}). Several of these genes reside within the same chromosomal band, calling into question their functional consequence. For example, *Keap1* and *Smarca4* are located on the same lost chromosomal band in mouse, in addition to two other cancer genes, *Icam5* and *Dnmt1*. Congruent transcriptional change was evident only for *Keap1* (correlation 0.48) and *Smarca4* (0.54), but was insufficient to distinguish the putative contribution of each given their similarity in prevalence and expression. Interestingly, these genes were all located on the same chromosomal band in human (*KEAP1/SMARCA4/ICAM5/DNMT1* on 19p13.2), further prohibiting functional disentanglement in human and mouse with these data. Additionally, *Met* and *Kras* reside on the same chromosome, but only in mouse. We interrogated the potential causal role of *Met* in tumors experiencing both *Kras* and *Met* CNA. By focusing on the genes that reside between *Kras* and *Met* on chromosome 6, we are able to delineate instances where *Met* CNA may be due to gain of the entire chromosome, from cases where *Kras* and *Met* appear to be amplified independently, suggesting that in some tumors *Met* may indeed be functionally relevant in the GEMM. Additional genes abrogated in human lung adenocarcinoma tumors and featured in ref. [@r18] were altered in NSCLC GEMM tumors, but did not meet our stringent criteria of significance and concurrent transcriptional impact, such as *Egfr* (25% gain), *Braf* (90% gain), *Arid1a* (7% loss), *Tert* (20% gain/amp), *Terc* (30% gain/amp), *Ccne1* (9% gain), and *Ccnd1* (9% gain) ([Dataset S6](#d35e1091){ref-type="supplementary-material"}). In summary, oncogenes and tumor suppressor genes, beyond those genetically engineered, are recurrently altered in established *KrasG12D* GEMM NSCLC tumors, and similar events are mirrored in *KRAS*-altered human tumors.

![Comparative analysis of genomic events and transcriptional landscapes between murine and human *KRAS*-altered NSCLC tumors. (*A*) Comparative analysis of the common alterations in *KRAS* mutant human and murine NSCLC tumors. Protein-altering mutations and copy number changes of established tumor suppressors and oncogenes are summarized by species. Gene and prevalence (fraction) within *Kras-*altered tumors are listed. (*B*) Transcript levels are significantly lower in tumors harboring *Keap1* losses compared with tumors with two copies. (*C*) NSCLC GEMM tumors with *Keap1* deletion demonstrated a significantly enhanced human lung-derived signature of *KEAP1* deficiency (*P* values as per Mann--Whitney) ([@r24]). See [Fig. S3*B*](#d35e486){ref-type="supplementary-material"} for expression of individual signature genes in NSCLC GEMM tumors.](pnas.1708391114fig03){#fig03}

*Stk11* and *Keap1* are the most prevalently altered genes that spontaneously occur in the NSCLC KP GEMM tumors and are shared with NSCLC patient tumors ([Fig. 1*E*](#fig01){ref-type="fig"}). Both genes experience loss-of-function mutations and copy number loss in human tumors. Contrarily, these alterations manifest solely as CNA in mouse tumors ([Fig. 3*A*](#fig03){ref-type="fig"}), and significantly reduced gene expression is observable in GEMM tumors with *Stk11* and *Keap1* genomic loss ([Fig. 3*B*](#fig03){ref-type="fig"} and [Fig. S3*A*](#d35e486){ref-type="supplementary-material"}). To further assess the functional relevance of these events in the murine tumors, we applied human lung-derived signatures of *KEAP1* and *STK11* deficiency ([@r24]) and demonstrate statistically significant association between signature expression and either *Keap1* or *Stk11* loss ([Fig. 3*C*](#fig03){ref-type="fig"} and [Fig. S3 *B*--*D*](#d35e486){ref-type="supplementary-material"}). These findings identify a functional impact of these genomic events on tumor signaling. Additionally, we found that these events significantly cooccur within *Kras*-mutant tumors in both species. In human, with *STK11* and *KEAP1* located on the same locus (19p13), 64% of tumors with *STK11* aberrations have concurrent *KEAP1* aberrations, and 80% of tumors with *KEAP1* aberrations have concurrent *STK11* aberrations (Fisher's exact test, *P* value 6*e*-7). In GEMM tumors, although those genes are located on different chromosomes, 56% of mouse tumors with *Stk11* loss show concurrent *Keap1* loss, and 43% of mouse tumors with *Keap1* loss show concurrent *Stk11* loss (Fisher's exact test, *P* = 0.03). Together, these data implicate a shared selective advantage in this biological context for these aberrations to cooccur in both murine and human lung tumors, irrespective of alteration type or chromosomal location.

Cooccurring Genomic Alterations in Murine and Human Kras Mutant PDAC Tumors. {#s6}
----------------------------------------------------------------------------

In contrast to the lung model, the PDAC KPP tumors developed with focal amplification of *KrasG12D* but no other recurrent PAMs or CNAs with residing cancer genes ([Fig. S1*B*](#d35e486){ref-type="supplementary-material"}). The PDAC KPR model, which differs in *Trp53* status (mutant in KPR) and *Cdkn2a* status (homozygous loss in KPP, heterozygous in KPR), also experiences *Kras* allelic imbalance, although to a lesser degree ([Fig. 2*B*](#fig02){ref-type="fig"}). In addition, the PDAC KPR tumors frequently demonstrated allelic imbalance at the *Trp53* locus, either through loss of wild type or gain of the mutant allele in 35% (14/40) of tumors ([Fig. S3*E*](#d35e486){ref-type="supplementary-material"}). Tumors with allelic imbalance of *Trp53* were not mutually exclusive to those with *Kras* CNAs in PDAC KPR tumors (Fisher's exact test, *P* = 0.70).

When comparing the most common genomic events in murine PDAC with human *KRAS*-altered PDAC, the engineered codrivers *Trp53* and *Cdkn2A* were also the most prominent in human ([Fig. 1*E*](#fig01){ref-type="fig"}), suggestive of the dominance of *Kras* and G1/S signaling in tumors from both species. *Smad4* loss was not observed in murine tumors, although alterations were observed for other *Tgfb* family members ([Datasets S7](#d35e1435){ref-type="supplementary-material"} and [S8](#d35e1438){ref-type="supplementary-material"}). Focal amplification of *Kras* was characteristic of PDAC GEMM tumors and is also seen in human *KRAS*-altered PDAC, although in only 5% of human tumors. To identify cooccurring events that harbor functional relevance within the tumors, we used the same criteria to align transcriptional changes to CNA (cancer genes with significant CNA by GISTIC2.0, and correlation ≥0.3 between CNA and expression in GEMM tumors); however, this yielded no additional events beyond those engineered ([Dataset S7](#d35e1435){ref-type="supplementary-material"} and [S8](#d35e1438){ref-type="supplementary-material"}). Together, these data indicate that the engineered alterations represent the most prevalent ones observed in human tumors and are sufficient for tumor initiation and development in PDAC.

Functional Impact of Kras Allelic Imbalance and Genomic Complexity. {#s7}
-------------------------------------------------------------------

With this overview of *Kras* allelic imbalance and cooccurring genomic events in the *Kras*-induced GEMM tumors, we sought to better understand the potential functional consequence of *Kras* CNA in the context of other genomic alterations. To do so, we exploited the matched tumor genomic and transcriptional profiles. First, we observed that the number of copies of *Kras* correlated with *Kras* expression ([Fig. S4*A*](#d35e486){ref-type="supplementary-material"}), and similarly, *KrasG12D* allele frequency correlated with expression of mutant *Kras* ([Fig. 4*A*](#fig04){ref-type="fig"}) across all tumor models. Although MAPK pathway target gene expression was elevated in all models relative to normal tissue ([Fig. S4*B*](#d35e486){ref-type="supplementary-material"}), these genes were consistently higher in PDAC KPP tumors ([Fig. 4*B*](#fig04){ref-type="fig"}). Moreover, expression of the signature genes highly correlated with increased *KrasG12D* allele frequency in PDAC KPP tumors ([Fig. 4*C*](#fig04){ref-type="fig"}). Interestingly, focal *KrasG12D* amplification was the only CNA or PAM found in these PDAC KPP tumors. The rare PDAC KPP tumors lacking focal *KrasG12D* amplification demonstrated copy number gain of genes capable of MAPK pathway activation, including *Pdgfra*, *Braf*, and *Ret*, which may underlie the consistent overexpression of MAPK target genes in this model. Metabolic changes have also been linked to *Kras* mutant expression and allele frequency ([@r25], [@r26]). Correlations with metabolism signatures were only observed in PDAC KPP tumors. *KrasG12D* allele frequency in KPP correlates significantly, although moderately with increased glycolysis/pentose phosphate pathway expression, as well as decreased peroxisome proliferator-activated receptor alpha (PPARA) and amino acid pathway expression ([Fig. 4*D*](#fig04){ref-type="fig"} and [Fig. S4*C*](#d35e486){ref-type="supplementary-material"}). In summary, correlations with *Kras* effector pathway signatures were strongest in PDAC KPP tumors where the primary genomic alteration is allelic imbalance of mutant *Kras*, in the absence of other recurrent PAM or CNA events. This suggests that *KrasG12D* mutation and CNA are sufficient to predict effector pathway enrichment in established tumors only when occurring in isolation of other events.

![Functional impact of *Kras* allelic imbalance and genomic complexity. (*A*) *KrasG12D* RNA allele fraction correlates with *KrasG12D* DNA allele frequency in PDAC KPP (*Left*), PDAC KPR (*Center*), and NSCLC tumors (*Right*); \*\*\*\**P* \< 0.0001. Pearson R shown. (*B*) Unsupervised clustering of MAPK target genes by tumors with model type overlaid. Log~2~ reads per kilobase of exon model per million (RPKM) expression data per gene is converted to a standard score. Blue indicates low-scaled expression, and yellow indicates high expression for each gene. (*C*) *KrasG12D* allele frequency is correlated with the MAPK expression signature in PDAC KPP tumors (in cyan, Spearman correlation 0.65, *P* = 4*e*-10) and to a lesser extent in PDAC KPR tumors (in red, 0.49, *P* = 0.001) and NSCLC tumors (in orange, 0.39, *P* = 4.3*e*-5). (*D*) Glycolytic activity as measured by the glycolysis/PPP expression signature is weakly associated with *KrasG12D* allele frequency in PDAC KPP (Spearman correlation 0.3, *P* = 0.009), and not associated in PDAC KPR (−0.12, NS) and NSCLC (0.06, NS). NS, *P* \> 0.05.](pnas.1708391114fig04){#fig04}

Differential Dependence on Mutant Kras in PDAC vs. NSCLC Tumors Under Selective Pressure of MAPK Pathway Inhibition. {#s8}
--------------------------------------------------------------------------------------------------------------------

Given the pronounced divergence of cooccurring spontaneous genomic events between NSCLC KP and PDAC KPP tumors, despite strong similarity with respect to *Kras* allelic imbalance (91% and 92%, respectively), we sought to interrogate how the heterogeneous allelic imbalance of *Kras* within these models is impacted under applied selective pressure. The underlying hypothesis was that in the absence of further gene modification, as in PDAC KPP, tumors would remain dependent on initiating events; whereas, in the context of high cooccurring genomic diversity, as with the NSCLC KP tumors, the initiating event may not be as critical. To test this hypothesis, we subjected both the PDAC KPP and NSCLC KP models to therapeutic intervention with MAPK pathway inhibitor combination treatment ([Fig. 5](#fig05){ref-type="fig"}). MAPK pathway inhibition significantly improved overall survival in the PDAC KPP model increasing the median survival by 53% (\>2 wk; [Fig. 5*A*](#fig05){ref-type="fig"}), demonstrating a clear dependence of this model on MAPK pathway signaling. Knowing that heterogeneous *Kras* CNAs characterize this model ([Fig. 2 *B* and *D*](#fig02){ref-type="fig"}), we assessed *Kras* status in terminal tumors. Following continuous MAPK pathway inhibition, PDAC KPP tumors were less heterogeneous, harboring a marked enrichment of cells with high *Kras* amplification ([Fig. 5*B*](#fig05){ref-type="fig"} and [Fig. S5*A*](#d35e486){ref-type="supplementary-material"}). Furthermore, tumors demonstrated a significant increase in the *KrasG12D* allele fraction ([Fig. 5*C*](#fig05){ref-type="fig"}). Exome sequencing confirmed that 83% of treated tumors had a *KrasG12D* allele frequency exceeding the 90th percentile of baseline tumors ([Fig. S5*B*](#d35e486){ref-type="supplementary-material"}). Progressing tumors also harbored MAPK target gene expression equivalent to vehicle tumors, despite continued drug treatment ([Fig. 5*D*](#fig05){ref-type="fig"}).

![Differential enrichment of *Kras* in PDAC and NSCLC tumors following therapeutic selective pressure of MAPK pathway inhibition. (*A*) Combination of MAPK pathway inhibition with a MEK inhibitor \[cobimetinib ([@r32]) at 5 mg/kg, PO, QD\] and ERK inhibitor \[GDC-0994 ([@r33]) at 60 mg/kg, PO, QD\] significantly increased overall survival of KPP PDAC animals (Log rank, \*\*\**P* = 0.0001). (*B*) FISH image from KPP PDAC before (*Left*) and after (*Right*) tumors for *Kras* (red) and a control gene (green). Four of seven tumors analyzed demonstrated dense *Kras* clusters indicative of high copy amplification per cell in 100% of tumor cells. (*C*) Ratio of *KrasG12D* relative to total *Kras* detected from genomic DNA of terminal tumors from experiment in *A* determined by droplet digital PCR (ddPCR) (Vehicle, *n* = 8; MAP*K*~i~ combo, *n* = 6; Mann--Whitney \**P* = 0.029). (*D*) MAPK signature derived from terminal tumors in *A* by Fluidigm (Vehicle, *n* = 8; MAPKi combo, *n* = 6; Mann--Whitney NS, not significant). (*E*) Combination of MAPK pathway inhibition significantly prolongs survival in NSCLC GEMM (Log rank, \*\**P* = 0.001). (*F*) Ratio of *KrasG12D* relative to total *Kras* detected from genomic DNA of terminal tumors from experiment in *E* determined by digital drop PCR (Vehicle, *n* = 9; MAPKi combo, *n* = 11). (*G*) MAPK signature derived from terminal tumors by Fluidigm (Vehicle, *n* = 10; MAPKi combo, *n* = 13; Mann--Whitney \*\*\**P* = 0.0006).](pnas.1708391114fig05){#fig05}

In the case of the NSCLC model, MAPK pathway inhibition also significantly improved overall survival increasing the median survival by 56% (\>6 wk; [Fig. 5*E*](#fig05){ref-type="fig"}), demonstrating similar dependence of this model on MAPK pathway signaling. Yet, in NSCLC KP terminal tumors selective pressure of drug treatment did not alter *KrasG12D* allele fraction ([Fig. 5*F*](#fig05){ref-type="fig"}). However, at progression, MAPK signaling is significantly lower in treated tumors relative to control tumors ([Fig. 5*G*](#fig05){ref-type="fig"}). Together, these results imply that pancreatic tumor cells with dramatically amplified *Kras* CNAs and high *KrasG12D* allele frequency have a selective advantage in the context of continuous, long-term MAPK pathway inhibition, while in NSCLC, mutant *Kras* does not.

Discussion {#s9}
==========

Past efforts to comprehensively define tumor genomes have revealed critical tumor dependencies that ultimately enabled the development of more effective therapeutics and treatments for patients. Preclinical experimentation guides the discovery and evaluation of therapeutic targets, making it vital to fully understand the extent and limits of their fidelity to human correlates. Through comprehensive genomic and transcriptomic analyses, we demonstrate that the widely used PDAC and NSCLC *KrasG12D*-initated GEMM tumors harbor previously unrecognized genomic diversity. Established oncogenes and tumor suppressor genes, beyond those engineered, are mutated, as well as recurrently amplified and deleted in tumors. The cooccurring genomic events significantly alter tumor transcriptomes indicative of a functional consequence that likely explains the transcriptional heterogeneity among tumors, despite sharing the *KrasG12D* initiating event.

It is unclear how the engineered alleles themselves, as well as the timing of acquisition, impact the evolutionary trajectory and heterogeneity. Use of distinct recombinases (i.e., Frt, Cre, Dre) combined with inducible elements (i.e., CreER, FlpOER, DreER) allow for temporal segregation of allele recombination, and conceptually, such tools could be used to better model the stepwise neoplastic transformation underlying human cancer. While temporally segregated recombination experiments extend beyond the scope of this current study, we anticipate that such research will provide unequivocal insight into the causality of each oncogenic lesion in compound genotypes. Additionally, whether alternate or multiple cells of tumor origin influence the genomic and transcriptional diversity among tumors remains a viable hypothesis. Another critical question is how such heterogeneity, irrespective of the origin, influences the signaling dependency of the established tumors, especially when under selective pressure, such as drug treatment or gene deletion. For example, it was recently reported that *Kras* copy number gain directs metabolic reprograming in NSCLC progression ([@r25]). However, correlations with metabolism signatures were only observed in PDAC KPP tumors, despite the fact that 92% of KP NSCLC tumors show *Kras* allelic imbalance ([Fig. 4*D*](#fig04){ref-type="fig"} and [Fig. S4*C*](#d35e486){ref-type="supplementary-material"}). It is plausible that metabolic rewiring that occurs early during tumor development is later masked due to further genetic evolution and complexity, as seen in the KP NSCLC tumors, whereas in the PDAC KPP tumors, the primary genomic alteration is allelic imbalance of mutant *Kras*, in the absence of other genetic events, so evidence of the correlation persists. Of course, direct testing of metabolic inhibitors would be necessary to determine the true relationship between *Kras* allelic imbalance, heterogeneity, and metabolic dependency in established tumors.

The intense subclonality and intertumoral and intratumoral heterogeneity of CNAs and PAMs, especially in the NSCLC KP tumors, confounds the possibility of testing "causality" for each genomic combination with respect to tumor maintenance. Such genomic diversity and subclonality has been recently acknowledged in human NSCLC as well ([@r27], [@r28]), emphasizing that identifying actionable drivers is challenging given such heterogeneity. In terms of the fidelity of GEMMs, the mutational burden is considerably less than their human tumor equivalents, consistent with previous reports of other GEMM tumors, which may compromise their utility in certain contexts. However, *Kras* mutant GEMM tumors, however, show abundant copy number alterations, some of which achieve the same functional outcome as mutations in human tumors, confirming the fidelity between altered genes and pathway signatures.

The diversity of the genomic landscape observed within these tumor models represents a previously unrecognized opportunity to potentially identify genomic subsets linked to therapeutic response or resistance. Using therapeutic inhibitors of the MAPK pathway, we observe that two models (NSCLC KP and PDAC KPP) respond to treatment; however, this selective pressure leads to distinct outcomes with regard to the susceptibility of *Kras*-mutant cells to treatment. Despite the differences in cooccurring genetic diversity between the two models, both models significantly responded to drug treatment, suggesting that both systems harbor MAPK-dependent tumors. We then exploited the therapy-progressed lesions to assess the impact of MAPK inhibition as a selective pressure on the initiating oncogene *Kras*. We discovered that in the context of PDAC KPP, therapy-resistant tumors enrich for highly amplified *Kras* cells, strongly indicative of a continued dependence on the initiating event. In recently published work using a *Kras*G12D acute myeloid leukemia (AML) model, where mutant *Kras* cooperates with disease-initiating retroviral insertions, allelic imbalance of *Kras* was found to increase susceptibility to MAPK inhibition ([@r29]). In contrast to our findings, the AML-relapsing tumor cells were nonamplified. It is notable that the heterogeneity and range of amplification is significantly higher in the PDAC KPP tumors. Moreover, it is likely that with enough *Kras* amplification, targeted therapies are unable to reduce signaling below the biologically meaningful threshold for effect. However, in the NSCLC KP tumors, therapy-resistant tumors demonstrate no change in the frequency of the *Kras* allele, suggesting no selective advantage in this context. It is tempting to speculate that the decreased dependency on amplified *Kras* in the NSCLC GEMM tumors is likely reflective of altered dependency on the initiating oncogene in the context of such genetic diversity, providing an enhanced fitness advantage and evolutionary flexibility. The fact that genomic evolution is occurring in these models provides a unique lens for these experimental models. Moreover, a more-thorough understanding of this unappreciated complexity in the context of both positive and negative outcomes observed in these model systems will ultimately allow for better interpretation and translatability of preclinical GEMM data for the benefit of cancer patients.

Materials and Methods {#s10}
=====================

GEMMs. {#s11}
------

We licensed mice from Tyler Jacks (Massachusetts Institute of Technology, Boston); Exelixis, Inc.; Anton Berns (Netherlands Cancer Institute, Amsterdam); and Andy Lowy (University of San Diego, San Diego) ([@r13], [@r14], [@r30], [@r31]). KPR and KPP mice were euthanized at median ages of 16.4 and 9 wk, respectively. One to three individual tumors, in addition to control tissue (muscle) for genomic analysis, were collected from each animal. NSCLC KP animals were intranasally infected with 5 × 10^6^ infectious units of adenovirus-expressing FLPe-IRES-Cre at ∼8 wk of age. These animals were euthanized between 25 and 33 wk of age, a time at which adenocarcinoma is present. All animals were monitored according to the guidelines from the Institutional Animal Care and Use Committee (IACUC) at Genentech, Inc. For in vivo dosing experimentation of models, animals were randomized into treatment cohorts by tumor measurement, with equal numbers of male and female animals. Cobimetinib (MEK inhibitor) ([@r32]) and GDC-0994 (ERK1/2 inhibitor) ([@r33]) were dosed at 5 mg/kg and 60 mg/kg by oral gavage (PO), daily (QD). The animals were dosed and monitored according to guidelines from the IACUC at Genentech, Inc. Animals were censored for survival in an unblinded manner based on predetermined morbidity criteria.

Genomic Profiling of GEMM Tumors and Comparison with Human KRAS-Altered Tumors. {#s12}
-------------------------------------------------------------------------------

Fluorescence in situ hybridization (FISH) was performed on the NSCLC and KPP GEMM tumors to verify copy number alterations of the *Kras* and *Keap1* genes. Transcriptional readouts of the MAPK pathway were assessed using the Fluidigm instrument. Genomic DNA was extracted from tumor and matched normal tissues for whole-exome sequencing. Total RNA was extracted from cells for RNA-sequencing. Data generated with HiSeq2500 (Illumina) were aligned to the mouse genome using GSNAP ([@r34]). For whole-exome sequencing, somatic single-nucleotide variants (SNV) and insertion/deletions (INDEL) were called using Strelka 1.0.4 ([@r35]). Protein altering mutations include nonsynonymous mutations, gain/loss of stop codon, insertion/deletion, and mutations at splicing donor and acceptor sites. Criteria for recurrent PAMs includes ≥2 events in at least two animals. We inferred the copy number landscape of each tumor from its exome sequence and the exome sequence of its matched normal, using Control-FREEC ([@r36]). We defined CNAs as copy number (CN) gain (2.8 ≤ CN \< 4), amplification (CN ≥ 4), loss (1 \< CN ≤ 1.4), and deletion (CN ≤ 1), and inferred their significance using GISTIC2.0 ([@r37]). Human cancer-related genes were obtained from [www.bushmanlab.org/links/genelists](http://www.bushmanlab.org/links/genelists), and subsampled to the CANgenes, Sanger, and Vogelstein lists. Metabolism signature genes were obtained from ref. [@r38]), and a cell line-derived signature of *KEAP1* deficiency from ref. [@r24]. We obtained clinical information, somatic mutation calls, and copy number status from cBioPortal and Firehose ([gdac.broadinstitute.org/runs/stddata\_\_2016_01_28/](http://gdac.broadinstitute.org/runs/stddata__2016_01_28/)), for *KRAS*-mutant lung adenocarcinoma tumors and pancreatic ductal adenocarcinoma tumors collected by the TCGA consortium ([@r18]). All source code and genomic data for the GEMMs are available at [research-pub.gene.com/Kras-mutant-GEMM](http://research-pub.gene.com/Kras-mutant-GEMM).
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